Anxiety Disorders

In this CME article, learn more about how to assess the impact of alcohol and cannabis use on anxiety treatment outcomes, recognizing potential adverse effects and interactions.

A book for all psychiatrists with woman patients and for all parents.

Social anxiety disorder: increased screening and recognition are essential for proper diagnosis, and psychotropic and psychotherapeutic options can be effective.

Perinatal mood and anxiety disorders affect 1 in 5 of perinatal individuals who are pregnant or up to 1 year postpartum. Over the past 2 decades, the US has seen an alarming rise in these disorders.

Careful consideration of the complex interplay between cultural identities, associations with beauty, and body-focused repetitive behaviors, may improve case conceptualization and treatment outcomes.

Guidelines from the World Health Organization's Mental Health Gap Action Program support nonspecialist health workers providing evidence-based treatments in underresourced regions.

Whether a patient has a diagnosis of cPTSD, BPD, or some combination of both, treatment should be considered multifaceted and overlapping. Learn more in this Special Report article.

An understanding of evolving risk factors and pathophysiology is vital to optimal clinical management of anxiety disorders and PTSD.

For those who have experienced trauma and suffer a subsequent mental health disorder, ongoing research is identifying psychotherapies, medications, and lifestyle changes that can help.

The FDA did not vote to deny approval of MDMA-assisted psychotherapy on June 4, 2024, contrary to all the buzz in the media saying they did. Learn more here.

Psychiatric Times wants to help you, as clinicians, support every patient.

Here are highlights from the week in Psychiatric Times.

Following the vote of the US Food and Drug Administration Psychopharmacologic Drugs Advisory Committee, Lykos has released a statement on MDMA-assisted therapy.

Experts shared the study results in a poster presentation at the 2024 ASCP Annual Meeting.

Here are highlights from the week in Psychiatric Times.

An expert discusses how the risks of benzodiazepine prescribing have been exaggerated in the minds of government officials, critics, and the public at large.

Psychiatric Times Editor-in-Chief shares his thoughts on the FDA Psychopharmacologic Drugs Advisory Committee decision for MDMA.

The FDA Psychopharmacologic Drugs Advisory Committee voted against recommending approval for psychedelic MDMA.

Write to us now to be part of our series focused on stress and anxiety this month.

The FDA Meeting of the Psychopharmacologic Drugs Advisory Committee evaluating the New Drug Application for MDMA is happening now. How do clinicians feel about this potential treatment for PTSD?

A lead educator and clinical consultant in the Lykos Therapeutics MDMA Therapist Education Program discusses MDMA-assisted therapy’s potential.

Some clinicians are skeptical about the potential of MDMA-assisted therapy...

If approved, how will MDMA-assisted therapy impact clinical psychiatry? The CEO of Lykos Therapeutics shares her thoughts.

In advance of the June 4 FDA Advisory Committee Meeting on MDMA-assisted therapy, we sat down with Alejandra Alva, MD, to get his first impressions.

What is new in research on stress and anxiety disorders?